Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: The Osteoporotic Fractures in Men (MrOS) study

ABSTRACT Normal mineral metabolism is critical for skeletal integrity, and recently serum fibroblast growth factor 23 (FGF23) levels were found to be directly related to overall fracture risk in elderly Swedish men. To confirm this association, we performed a prospective case‐cohort study to underst...

Full description

Saved in:
Bibliographic Details
Published in:Journal of bone and mineral research Vol. 28; no. 11; pp. 2325 - 2332
Main Authors: Lane, Nancy E, Parimi, Neeta, Corr, Maripat, Yao, Wei, Cauley, Jane A, Nielson, Carrie M, Ix, Joseph H, Kado, Deborah, Orwoll, Eric
Format: Journal Article
Language:English
Published: United States Wiley Subscription Services, Inc 01-11-2013
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract ABSTRACT Normal mineral metabolism is critical for skeletal integrity, and recently serum fibroblast growth factor 23 (FGF23) levels were found to be directly related to overall fracture risk in elderly Swedish men. To confirm this association, we performed a prospective case‐cohort study to understand the relation of FGF23 and fracture risk in older white men enrolled in the Osteoporotic Fractures in Men (MrOS) study. In the cohort of 5994 men attending the baseline MrOS examination, we evaluated a subgroup of 387 men with incident nonvertebral fracture including 73 hip fractures and a sample of 1385 men randomly selected from the cohort with baseline mineral and calcium hormone measurements. FGF23 was measured in baseline serum samples by ELISA (Millipore, Billerica, MA, USA). Modified Cox proportional hazards models that account for case‐cohort study design were used to estimate the relative hazards (RH) of fracture in men across quartiles of FGF23. Subjects were also stratified by renal function, and RH per strata was estimated in men with the highest quartile of FGF23 compared with quartiles 3, 2, and 1. Overall, there was no difference in risk of nonspine or hip fracture by baseline FGF23. However, associations differed by strata of eGFRCrCy. Among men with eGFRCrCys <60 mL/min/1.73 m2 (n = 73/313 nonspine fractures), the RH in the highest quartile of FGF23 compared with the rest was 2.02 (95% confidence interval [CI] 1.07–3.79), but in men with eGFRCrCy, >60 mL/min/1.73 m2 (304/1370 fractures) the RH was 0.91 (95% CI 0.66–1.25) after adjustment for age, clinic site, body mass index, race, total hip bone mineral density, vitamin D, parathyroid hormone, alcohol use, physical activity, fracture history, and serum phosphorus. Serum FGF23 levels are not associated with incident fractures in elderly men overall. However, higher levels of serum FGF23 are associated with fracture risk in those with poor renal function. © 2013 American Society for Bone and Mineral Research.
AbstractList Normal mineral metabolism is critical for skeletal integrity, and recently serum fibroblast growth factor 23 (FGF23) levels were found to be directly related to overall fracture risk in elderly Swedish men. To confirm this association, we performed a prospective case-cohort study to understand the relation of FGF23 and fracture risk in older white men enrolled in the Osteoporotic Fractures in Men (MrOS) study. In the cohort of 5994 men attending the baseline MrOS examination, we evaluated a subgroup of 387 men with incident nonvertebral fracture including 73 hip fractures and a sample of 1385 men randomly selected from the cohort with baseline mineral and calcium hormone measurements. FGF23 was measured in baseline serum samples by ELISA (Millipore, Billerica, MA, USA). Modified Cox proportional hazards models that account for case-cohort study design were used to estimate the relative hazards (RH) of fracture in men across quartiles of FGF23. Subjects were also stratified by renal function, and RH per strata was estimated in men with the highest quartile of FGF23 compared with quartiles 3, 2, and 1. Overall, there was no difference in risk of nonspine or hip fracture by baseline FGF23. However, associations differed by strata of eGFRCrCy . Among men with eGFRCrCys <60 mL/min/1.73 m2 (n = 73/313 nonspine fractures), the RH in the highest quartile of FGF23 compared with the rest was 2.02 (95% confidence interval [CI] 1.07-3.79), but in men with eGFRCrCy , >60 mL/min/1.73 m2 (304/1370 fractures) the RH was 0.91 (95% CI 0.66-1.25) after adjustment for age, clinic site, body mass index, race, total hip bone mineral density, vitamin D, parathyroid hormone, alcohol use, physical activity, fracture history, and serum phosphorus. Serum FGF23 levels are not associated with incident fractures in elderly men overall. However, higher levels of serum FGF23 are associated with fracture risk in those with poor renal function.
Normal mineral metabolism is critical for skeletal integrity, and recently serum fibroblast growth factor 23 (FGF23) levels were found to be directly related to overall fracture risk in elderly Swedish men. To confirm this association, we performed a prospective case-cohort study to understand the relation of FGF23 and fracture risk in older white men enrolled in the Osteoporotic Fractures in Men (MrOS) study. In the cohort of 5994 men attending the baseline MrOS examination, we evaluated a subgroup of 387 men with incident nonvertebral fracture including 73 hip fractures and a sample of 1385 men randomly selected from the cohort with baseline mineral and calcium hormone measurements. FGF23 was measured in baseline serum samples by ELISA (Millipore, Billerica, MA, USA). Modified Cox proportional hazards models that account for case-cohort study design were used to estimate the relative hazards (RH) of fracture in men across quartiles of FGF23. Subjects were also stratified by renal function, and RH per strata was estimated in men with the highest quartile of FGF23 compared with quartiles 3, 2, and 1. Overall, there was no difference in risk of nonspine or hip fracture by baseline FGF23. However, associations differed by strata of eGFRCrCy. Among men with eGFRCrCys <60mL/min/1.73m2 (n=73/313 nonspine fractures), the RH in the highest quartile of FGF23 compared with the rest was 2.02 (95% confidence interval [CI] 1.07-3.79), but in men with eGFRCrCy, >60mL/min/1.73m2 (304/1370 fractures) the RH was 0.91 (95% CI 0.66-1.25) after adjustment for age, clinic site, body mass index, race, total hip bone mineral density, vitamin D, parathyroid hormone, alcohol use, physical activity, fracture history, and serum phosphorus. Serum FGF23 levels are not associated with incident fractures in elderly men overall. However, higher levels of serum FGF23 are associated with fracture risk in those with poor renal function. © 2013 American Society for Bone and Mineral Research. [PUBLICATION ABSTRACT]
ABSTRACT Normal mineral metabolism is critical for skeletal integrity, and recently serum fibroblast growth factor 23 (FGF23) levels were found to be directly related to overall fracture risk in elderly Swedish men. To confirm this association, we performed a prospective case‐cohort study to understand the relation of FGF23 and fracture risk in older white men enrolled in the Osteoporotic Fractures in Men (MrOS) study. In the cohort of 5994 men attending the baseline MrOS examination, we evaluated a subgroup of 387 men with incident nonvertebral fracture including 73 hip fractures and a sample of 1385 men randomly selected from the cohort with baseline mineral and calcium hormone measurements. FGF23 was measured in baseline serum samples by ELISA (Millipore, Billerica, MA, USA). Modified Cox proportional hazards models that account for case‐cohort study design were used to estimate the relative hazards (RH) of fracture in men across quartiles of FGF23. Subjects were also stratified by renal function, and RH per strata was estimated in men with the highest quartile of FGF23 compared with quartiles 3, 2, and 1. Overall, there was no difference in risk of nonspine or hip fracture by baseline FGF23. However, associations differed by strata of eGFRCrCy. Among men with eGFRCrCys <60 mL/min/1.73 m2 (n = 73/313 nonspine fractures), the RH in the highest quartile of FGF23 compared with the rest was 2.02 (95% confidence interval [CI] 1.07–3.79), but in men with eGFRCrCy, >60 mL/min/1.73 m2 (304/1370 fractures) the RH was 0.91 (95% CI 0.66–1.25) after adjustment for age, clinic site, body mass index, race, total hip bone mineral density, vitamin D, parathyroid hormone, alcohol use, physical activity, fracture history, and serum phosphorus. Serum FGF23 levels are not associated with incident fractures in elderly men overall. However, higher levels of serum FGF23 are associated with fracture risk in those with poor renal function. © 2013 American Society for Bone and Mineral Research.
Normal mineral metabolism is critical for skeletal integrity and recently serum fibroblast Growth factor 23 (FGF23) levels were found to be directly related to overall fracture risk in elderly Swedish Men. To confirm this association, we performed a prospective case-cohort study to understand the relation of FGF23 and fracture risk in older Caucasian men enrolled in the Osteoporotic Fractures in Men (MrOS) Study.
Normal mineral metabolism is critical for skeletal integrity, and recently serum fibroblast growth factor 23 (FGF23) levels were found to be directly related to overall fracture risk in elderly Swedish men. To confirm this association, we performed a prospective case-cohort study to understand the relation of FGF23 and fracture risk in older white men enrolled in the Osteoporotic Fractures in Men (MrOS) study. In the cohort of 5994 men attending the baseline MrOS examination, we evaluated a subgroup of 387 men with incident nonvertebral fracture including 73 hip fractures and a sample of 1385 men randomly selected from the cohort with baseline mineral and calcium hormone measurements. FGF23 was measured in baseline serum samples by ELISA (Millipore, Billerica, MA, USA). Modified Cox proportional hazards models that account for case-cohort study design were used to estimate the relative hazards (RH) of fracture in men across quartiles of FGF23. Subjects were also stratified by renal function, and RH per strata was estimated in men with the highest quartile of FGF23 compared with quartiles 3, 2, and 1. Overall, there was no difference in risk of nonspine or hip fracture by baseline FGF23. However, associations differed by strata of eGFR sub(CrCy). Among men with eGFR sub(CrCys) < 60mL/min/1.73 m super(2) (n = 73/313 nonspine fractures), the RH in the highest quartile of FGF23 compared with the rest was 2.02 (95% confidence interval [CI] 1.07-3.79), but in men with eGFR sub(CrCy), > 60 mL/min/1.73 m super(2) (304/1370 fractures) the RH was 0.91 (95% CI 0.66-1.25) after adjustment for age, clinic site, body mass index, race, total hip bone mineral density, vitamin D, parathyroid hormone, alcohol use, physical activity, fracture history, and serum phosphorus. Serum FGF23 levels are not associated with incident fractures in elderly men overall. However, higher levels of serum FGF23 are associated with fracture risk in those with poor renal function.
Author Lane, Nancy E
Orwoll, Eric
Kado, Deborah
Cauley, Jane A
Yao, Wei
Corr, Maripat
Parimi, Neeta
Nielson, Carrie M
Ix, Joseph H
AuthorAffiliation 1 University of California at Davis, Sacramento
3 University of California, San Diego
5 Oregon Health & Science University, Portland OR
4 University of Pittsburgh, Pittsburgh, PA
2 California Pacific Medical Center Research Institute, San Francisco, CA
AuthorAffiliation_xml – name: 3 University of California, San Diego
– name: 5 Oregon Health & Science University, Portland OR
– name: 1 University of California at Davis, Sacramento
– name: 2 California Pacific Medical Center Research Institute, San Francisco, CA
– name: 4 University of Pittsburgh, Pittsburgh, PA
Author_xml – sequence: 1
  givenname: Nancy E
  surname: Lane
  fullname: Lane, Nancy E
  organization: Sacramento
– sequence: 2
  givenname: Neeta
  surname: Parimi
  fullname: Parimi, Neeta
  organization: San Francisco
– sequence: 3
  givenname: Maripat
  surname: Corr
  fullname: Corr, Maripat
  organization: San Diego
– sequence: 4
  givenname: Wei
  surname: Yao
  fullname: Yao, Wei
  organization: Sacramento
– sequence: 5
  givenname: Jane A
  surname: Cauley
  fullname: Cauley, Jane A
  organization: Pittsburgh
– sequence: 6
  givenname: Carrie M
  surname: Nielson
  fullname: Nielson, Carrie M
  organization: Portland
– sequence: 7
  givenname: Joseph H
  surname: Ix
  fullname: Ix, Joseph H
  organization: Portland
– sequence: 8
  givenname: Deborah
  surname: Kado
  fullname: Kado, Deborah
  organization: San Diego
– sequence: 9
  givenname: Eric
  surname: Orwoll
  fullname: Orwoll, Eric
  organization: Portland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23677793$$D View this record in MEDLINE/PubMed
BookMark eNqNkt9qFDEUh4NU7LZ64QtIwJvdi2nzPxMvhFrcqnRZ0HodMjNJN8tMsiYzln0HH9oZt5YqCN4kkPPxkXPO7wQchRgsAC8xOsMIkfNt1aUzrEr-BMwwJ7RgosRHYIbKkhWIUXwMTnLeIoQEF-IZOCZUSCkVnYEfFznH2pvexwCjg9mmoYPOVylWrck9vE3xrt9AZ-o-JkgonC-vloQuoAkN9KH2jQ09dGmsD8nm8QnGtrEJdja8gTcbC9e5t3EXU-x9DZePwZUNcL5K6y8LmPuh2T8HT51ps31xf5-Cr8v3N5cfiuv11cfLi-ui5ozwouLKYY4bzqghuKnGg2ChiGPOCUGYcYo2kiHDlSKSSudwjSQluLTMcm7oKXh78O6GqrNNPXaQTKt3yXcm7XU0Xv9ZCX6jb-N3TUvESyxHwfxekOK3weZedz7Xtm1NsHHIGjPBOJKciP9AGVVKUTJZX_-FbuOQwjiJiSKS0ZKykVocqDrFnJN1D__GSE9x0FMc9BSHkX31uNEH8vf-R-D8ANz51u7_bdKf3q0-_1L-BAv-wG8
CODEN JBMREJ
CitedBy_id crossref_primary_10_1111_nep_12319
crossref_primary_10_1007_s00198_021_06001_6
crossref_primary_10_1177_1759720X15621227
crossref_primary_10_1155_2017_3485785
crossref_primary_10_1002_jbmr_3900
crossref_primary_10_1016_j_rhum_2016_06_006
crossref_primary_10_1016_j_jdiacomp_2019_107476
crossref_primary_10_1080_08977194_2023_2274579
crossref_primary_10_1016_j_exphem_2020_09_190
crossref_primary_10_1186_s12979_017_0097_0
crossref_primary_10_1007_s40291_017_0272_1
crossref_primary_10_3389_fendo_2023_1152464
crossref_primary_10_1016_j_jocd_2014_01_010
crossref_primary_10_1002_jbmr_4443
crossref_primary_10_1002_jbmr_2487
crossref_primary_10_1016_j_medcli_2014_01_008
crossref_primary_10_1002_jbm4_10697
crossref_primary_10_1016_j_bone_2024_117123
crossref_primary_10_1186_s40001_018_0315_z
crossref_primary_10_1007_s00198_018_4598_2
crossref_primary_10_1016_j_bone_2021_115885
crossref_primary_10_1016_j_jbspin_2016_09_022
crossref_primary_10_3390_ijms25094875
crossref_primary_10_1007_s00424_014_1625_9
crossref_primary_10_1016_j_bone_2014_05_016
crossref_primary_10_1093_rheumatology_kev410
crossref_primary_10_5604_16652681_1231580
crossref_primary_10_1007_s00198_019_04996_7
crossref_primary_10_1371_journal_pone_0133278
crossref_primary_10_1186_s12882_021_02393_z
crossref_primary_10_1016_j_bone_2016_03_005
crossref_primary_10_1007_s40620_017_0410_1
crossref_primary_10_1089_rej_2013_1475
crossref_primary_10_1016_j_bbrc_2015_10_018
crossref_primary_10_1002_jbmr_2750
crossref_primary_10_1210_jc_2016_4038
crossref_primary_10_1016_j_bone_2020_115777
crossref_primary_10_3390_diagnostics10030145
crossref_primary_10_1002_pbc_25188
crossref_primary_10_1016_j_bone_2017_02_005
crossref_primary_10_1111_cen_13981
crossref_primary_10_1210_clinem_dgac071
crossref_primary_10_2215_CJN_07060714
crossref_primary_10_3390_ijms23052500
Cites_doi 10.1002/jbmr.5650110716
10.1359/JBMR.0301264
10.1056/NEJMoa1114248
10.1053/j.ajkd.2007.11.018
10.1152/ajpendo.90201.2008
10.1038/ki.2010.194
10.1359/jbmr.080220
10.1093/biomet/73.1.1
10.1038/ki.2011.47
10.1002/jbmr.263
10.1007/s00467-012-2309-3
10.1002/jor.20857
10.1111/j.1523-1755.2005.00178.x
10.1111/j.1744-9987.2005.00293.x
10.1111/j.1532-5415.2010.03245.x
10.1210/en.2003-1768
10.1074/jbc.C500457200
10.1146/annurev.physiol.69.040705.141729
10.1359/jbmr.2003.18.7.1227
10.1053/j.ajkd.2011.05.019
10.1016/j.cct.2005.05.005
10.1152/ajprenal.00199.2012
10.1002/jbmr.1810
10.1210/jc.2008-2786
10.1093/jmicro/dfp032
10.1016/j.cct.2005.05.006
10.1210/jc.2006-0710
10.1080/00365519950185940
10.1359/jbmr.061017
10.1038/ng1905
ContentType Journal Article
Copyright 2013 American Society for Bone and Mineral Research
2013 American Society for Bone and Mineral Research.
Copyright_xml – notice: 2013 American Society for Bone and Mineral Research
– notice: 2013 American Society for Bone and Mineral Research.
CorporateAuthor Osteoporotic Fractures in Men (MrOS) Study Group
for the Osteoporotic Fractures in Men (MrOS) Study Group
CorporateAuthor_xml – name: Osteoporotic Fractures in Men (MrOS) Study Group
– name: for the Osteoporotic Fractures in Men (MrOS) Study Group
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7TS
K9.
7X8
5PM
DOI 10.1002/jbmr.1985
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
Physical Education Index
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Calcium & Calcified Tissue Abstracts
Physical Education Index
MEDLINE - Academic
DatabaseTitleList MEDLINE
ProQuest Health & Medical Complete (Alumni)


Calcium & Calcified Tissue Abstracts
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1523-4681
EndPage 2332
ExternalDocumentID 3102292801
10_1002_jbmr_1985
23677793
JBMR1985
Genre article
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
– fundername: NIH Roadmap for Medical Research
  funderid: U01 AR45580; U01 AR45614; U01 AR45632; U01 AR45647; U01 AR45654; U01 AR45583; U01 AG18197; U01‐AG027810; UL1 RR024140
– fundername: National Institute on Aging (NIA)
– fundername: National Center for Research Resources (NCRR)
– fundername: NIAMS NIH HHS
  grantid: K01 AR062655
– fundername: NIAMS NIH HHS
  grantid: U01 AR045583
– fundername: NIAMS NIH HHS
  grantid: U01 AR45583
– fundername: NIAMS NIH HHS
  grantid: U01 AR045614
– fundername: NIAMS NIH HHS
  grantid: U01 AR045580
– fundername: NIAMS NIH HHS
  grantid: U01 AR045632
– fundername: NIAMS NIH HHS
  grantid: U01 AR45614
– fundername: NIAMS NIH HHS
  grantid: U01 AR45654
– fundername: NIAMS NIH HHS
  grantid: U01 AR45647
– fundername: NIAMS NIH HHS
  grantid: U01 AR045647
– fundername: National Center for Research Resources : NCRR
  grantid: UL1 RR024140 || RR
– fundername: National Institute on Aging : NIA
  grantid: U01 AG018197 || AG
– fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases : NIAMS
  grantid: U01 AR045614 || AR
– fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases : NIAMS
  grantid: U01 AR045647 || AR
– fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases : NIAMS
  grantid: U01 AR045580 || AR
– fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases : NIAMS
  grantid: U01 AR045632 || AR
– fundername: National Institute on Aging : NIA
  grantid: U01 AG027810 || AG
– fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases : NIAMS
  grantid: U01 AR045583 || AR
– fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases : NIAMS
  grantid: U01 AR045654 || AR
– fundername: National Institute of Arthritis and Musculoskeletal and Skin Diseases : NIAMS
  grantid: K24 AR048841 || AR
GroupedDBID ---
.55
.GJ
05W
0R~
1OB
1OC
24P
29K
2WC
31~
33P
3SF
3WU
4.4
50Y
52U
53G
5GY
5RE
5WD
66C
8-0
8-1
A00
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AAPXW
AASGY
AAUAY
AAXRX
AAZKR
ABCUV
ABEFU
ABJNI
ABNHQ
ABQNK
ABXGK
ABXVV
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ACZBC
ADBTR
ADEOM
ADIPN
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFGKR
AFPWT
AFZJQ
AGMDO
AHMBA
AIACR
AIURR
AIWBW
AJAOE
AJBDE
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVNTJ
AVWKF
AZBYB
AZFZN
AZVAB
BCRHZ
BDRZF
BFHJK
BHBCM
BMXJE
BNHUX
BOGZA
BQCPF
BRXPI
CS3
D-I
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
F5P
FEDTE
FUBAC
G-S
GK1
GODZA
HVGLF
HZ~
IJI
IX1
KBYEO
LATKE
LEEKS
LITHE
LOXES
LUTES
LYRES
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
NNB
O66
O9-
OCZFY
OJZSN
OK1
OVD
OWPYF
P2P
P2W
P4E
PALCI
PQQKQ
R.K
RIG
RIWAO
RJQFR
ROL
ROX
RWI
RX1
SJN
SUPJJ
TEORI
TR2
VJK
W99
WBKPD
WIH
WIJ
WIK
WNSPC
WOHZO
WYISQ
WYJ
X7M
XV2
ZGI
ZXP
ZZTAW
~S-
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
ABEJV
CITATION
7QP
7TS
K9.
7X8
5PM
ID FETCH-LOGICAL-c5425-b59f151d543a21dba2121692f4ff6624af93d740a5992737ff1c073218e4e55a3
IEDL.DBID 33P
ISSN 0884-0431
IngestDate Tue Sep 17 20:56:38 EDT 2024
Fri Oct 25 03:02:50 EDT 2024
Fri Oct 25 02:50:15 EDT 2024
Thu Oct 10 14:26:14 EDT 2024
Thu Nov 21 21:11:04 EST 2024
Sat Sep 28 08:32:18 EDT 2024
Sat Aug 24 00:57:09 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords FGF23
OSTEOPOROSIS
MEN
Language English
License 2013 American Society for Bone and Mineral Research.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5425-b59f151d543a21dba2121692f4ff6624af93d740a5992737ff1c073218e4e55a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jbmr.1985
PMID 23677793
PQID 1442743834
PQPubID 1006376
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3805817
proquest_miscellaneous_1464507526
proquest_miscellaneous_1443999327
proquest_journals_1442743834
crossref_primary_10_1002_jbmr_1985
pubmed_primary_23677793
wiley_primary_10_1002_jbmr_1985_JBMR1985
PublicationCentury 2000
PublicationDate November 2013
PublicationDateYYYYMMDD 2013-11-01
PublicationDate_xml – month: 11
  year: 2013
  text: November 2013
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Baltimore
PublicationTitle Journal of bone and mineral research
PublicationTitleAlternate J Bone Miner Res
PublicationYear 2013
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2004; 145
2010; 78
2006; 91
2013; 28
1986; 73
2006; 38
2007
1996
2011; 79
2003; 18
2011; 59
2011; 58
2005; 26
2012; 367
2008; 51
2012; 303
2009; 27
2005; 67
2009; 58
2004; 19
2009; 94
2005; 9
1999; 59
2008; 23
2012; 28
2011; 26
2006; 281
2007; 22
2008; 295
2007; 69
Bonewald (2024020318340624200_jbmr1985-bib-0005) 2013; 28
Ubaidus (2024020318340624200_jbmr1985-bib-0024) 2009; 58
Wšhrle (2024020318340624200_jbmr1985-bib-0030) 2012; 28
Mirza (2024020318340624200_jbmr1985-bib-0003) 2011; 26
Erlandsen (2024020318340624200_jbmr1985-bib-0014) 1999; 59
Kurosu (2024020318340624200_jbmr1985-bib-0027) 2006; 281
Shimada (2024020318340624200_jbmr1985-bib-0002) 2004; 19
Stevens (2024020318340624200_jbmr1985-bib-0016) 2008; 51
Goebel (2024020318340624200_jbmr1985-bib-0028) 2009; 27
Inker (2024020318340624200_jbmr1985-bib-0017) 2012; 367
Krieger (2024020318340624200_jbmr1985-bib-0029) 2012; 303
Singh (2024020318340624200_jbmr1985-bib-0013) 2006; 91
Isakova (2024020318340624200_jbmr1985-bib-0022) 2011; 79
Weber (2024020318340624200_jbmr1985-bib-0018) 2003; 18
Ensrud (2024020318340624200_jbmr1985-bib-0020) 2009; 94
Berndt (2024020318340624200_jbmr1985-bib-0001) 2007; 69
Wang (2024020318340624200_jbmr1985-bib-0023) 2008; 23
Koiwa (2024020318340624200_jbmr1985-bib-0032) 2005; 9
Blank (2024020318340624200_jbmr1985-bib-0009) 2005; 26
Larsson (2024020318340624200_jbmr1985-bib-0007) 2004; 145
Orwoll (2024020318340624200_jbmr1985-bib-0008) 2005; 26
Lewis (2024020318340624200_jbmr1985-bib-0011) 2007; 22
Genant (2024020318340624200_jbmr1985-bib-0012) 1996
Lee (2024020318340624200_jbmr1985-bib-0021) 2011; 59
Kazama (2024020318340624200_jbmr1985-bib-0031) 2005; 67
Liu (2024020318340624200_jbmr1985-bib-0026) 2008; 295
Inker (2024020318340624200_jbmr1985-bib-0015) 2011; 58
Feng (2024020318340624200_jbmr1985-bib-0004) 2006; 38
Prentice (2024020318340624200_jbmr1985-bib-0010) 1986; 73
Weber (2024020318340624200_jbmr1985-bib-0025) 2003; 18
Bonewald (2024020318340624200_jbmr1985-bib-0006) 2007
Yilmaz (2024020318340624200_jbmr1985-bib-0019) 2010; 78
References_xml – volume: 26
  start-page: 569
  issue: 5
  year: 2005
  end-page: 85
  article-title: Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study—a large observational study of the determinants of fracture in older men
  publication-title: Contemp Clin Trials.
– volume: 28
  start-page: 563
  issue: 4
  year: 2013
  end-page: 8
  article-title: FGF23 production by osteocytes
  publication-title: Pediatr Nephrol.
– volume: 79
  start-page: 1370
  issue: 12
  year: 2011
  end-page: 8
  article-title: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
  publication-title: Kidney Int.
– start-page: 984
  year: 1996
  end-page: 96
  article-title: Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis
  publication-title: J Bone Miner Res.
– volume: 145
  start-page: 3087
  year: 2004
  end-page: 94
  article-title: Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha I collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis
  publication-title: Endocrinology.
– volume: 38
  start-page: 1310
  year: 2006
  end-page: 5
  article-title: Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism
  publication-title: Nat Genet.
– volume: 367
  start-page: 20
  issue: 1
  year: 2012
  end-page: 9
  article-title: Levey AS; CKD‐EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C
  publication-title: N Engl J Med.
– volume: 26
  start-page: 557
  issue: 5
  year: 2005
  end-page: 68
  article-title: Overview of recruitment for the osteoporotic fractures in men study (MrOS)
  publication-title: Contemp Clin Trials.
– volume: 58
  start-page: 381
  issue: 6
  year: 2009
  end-page: 92
  article-title: FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling
  publication-title: J Electron Microsc (Tokyo).
– volume: 9
  start-page: 336
  year: 2005
  end-page: 9
  article-title: Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients
  publication-title: Ther Apher Dial.
– volume: 73
  start-page: 1
  year: 1986
  end-page: 11
  article-title: A case‐control design for epidemiologic cohort studies and disease prevention trials
  publication-title: Biometricka.
– volume: 59
  start-page: 1
  issue: 1
  year: 1999
  end-page: 8
  article-title: Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System
  publication-title: Scand J Clin Lab Invest.
– volume: 23
  start-page: 939
  issue: 6
  year: 2008
  end-page: 48
  article-title: Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro
  publication-title: J Bone Miner Res.
– volume: 27
  start-page: 1141
  issue: 9
  year: 2009
  end-page: 6
  article-title: FGF23 is a putative marker for bone healing and regeneration
  publication-title: J Orthop Res.
– start-page: 169
  year: 2007
  end-page: 90
– volume: 22
  start-page: 211
  issue: 2
  year: 2007
  end-page: 9
  article-title: Predictors of nonspine fracture in elderly men: the MrOS study
  publication-title: J Bone Miner Res.
– volume: 91
  start-page: 3055
  issue: 8
  year: 2006
  end-page: 61
  article-title: C‐3 epimers can account for a significant proportion of total circulating 25‐hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status
  publication-title: J Clin Endocrinol Metab.
– volume: 26
  start-page: 857
  year: 2011
  end-page: 64
  article-title: Serum fibroblast growth factor‐23 (FFGF‐23) and fracture risk in elderly men
  publication-title: J Bone Miner Res.
– volume: 69
  start-page: 341
  year: 2007
  end-page: 59
  article-title: Phosphatonins and the regulation of phosphate homeostasis
  publication-title: Annu Rev Physiolo.
– volume: 59
  start-page: 233
  year: 2011
  end-page: 40
  article-title: Mortality risk in older men associated with changes in weight, lean mass, and fat mass
  publication-title: J Am Geriatr Soc.
– volume: 28
  start-page: 899
  issue: 4
  year: 2012
  end-page: 911
  article-title: Pharmacological inhibition of FGFR signaling ameliorates FGF23‐mediated hypophosphatemic rickets
  publication-title: J Bone Miner Res.
– volume: 51
  start-page: 395
  year: 2008
  end-page: 406
  article-title: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD
  publication-title: Am J Kidney Dis.
– volume: 78
  start-page: 679
  year: 2010
  end-page: 85
  article-title: FGF‐23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease
  publication-title: Kidney Int.
– volume: 281
  start-page: 6120
  issue: 10
  year: 2006
  end-page: 3
  article-title: Regulation of fibroblast growth factor‐23 signaling by klotho
  publication-title: J Biol Chem.
– volume: 295
  start-page: E254
  issue: 2
  year: 2008
  end-page: 61
  article-title: Pathogenic role of Fgf23 in Dmp1‐null mice
  publication-title: Am J Physiol Endocrinol Metab.
– volume: 58
  start-page: 682
  year: 2011
  end-page: 4
  article-title: Expressing the CKD‐EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values
  publication-title: Am J Kidney Dis.
– volume: 94
  start-page: 2773
  year: 2009
  end-page: 80
  article-title: Serum 25‐hydroxyvitamin D levels and rate of hip bone loss in older men
  publication-title: J Clin Endocrinol Metab.
– volume: 303
  start-page: F431
  issue: 3
  year: 2012
  end-page: 6
  article-title: Metabolic acisois increase fibroblast growth factor 23 in neomatula mouse bone
  publication-title: Am J Physiol Renal Physiol.
– volume: 19
  start-page: 429
  year: 2004
  end-page: 35
  article-title: FGF‐23 is a potent regulator of vitamin D metabolism and phosphonate homeostasis
  publication-title: J Bone Miner Res.
– volume: 18
  start-page: 1227
  issue: 7
  year: 2003
  end-page: 34
  article-title: Serum FGF23 levels in normal and disordered phosphorus homeostasis
  publication-title: J Bone Miner Res.
– volume: 67
  start-page: 1120
  year: 2005
  end-page: 5
  article-title: Pretreatment serum FGF‐23 levels predict the efficacy of calcitriol therapy in dialysis patients
  publication-title: Kidney Int.
– start-page: 984
  year: 1996
  ident: 2024020318340624200_jbmr1985-bib-0012
  article-title: Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis
  publication-title: J Bone Miner Res.
  doi: 10.1002/jbmr.5650110716
  contributor:
    fullname: Genant
– volume: 19
  start-page: 429
  year: 2004
  ident: 2024020318340624200_jbmr1985-bib-0002
  article-title: FGF-23 is a potent regulator of vitamin D metabolism and phosphonate homeostasis
  publication-title: J Bone Miner Res.
  doi: 10.1359/JBMR.0301264
  contributor:
    fullname: Shimada
– volume: 367
  start-page: 20
  issue: 1
  year: 2012
  ident: 2024020318340624200_jbmr1985-bib-0017
  article-title: Levey AS; CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1114248
  contributor:
    fullname: Inker
– volume: 51
  start-page: 395
  year: 2008
  ident: 2024020318340624200_jbmr1985-bib-0016
  article-title: Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD
  publication-title: Am J Kidney Dis.
  doi: 10.1053/j.ajkd.2007.11.018
  contributor:
    fullname: Stevens
– volume: 295
  start-page: E254
  issue: 2
  year: 2008
  ident: 2024020318340624200_jbmr1985-bib-0026
  article-title: Pathogenic role of Fgf23 in Dmp1-null mice
  publication-title: Am J Physiol Endocrinol Metab.
  doi: 10.1152/ajpendo.90201.2008
  contributor:
    fullname: Liu
– volume: 78
  start-page: 679
  year: 2010
  ident: 2024020318340624200_jbmr1985-bib-0019
  article-title: FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease
  publication-title: Kidney Int.
  doi: 10.1038/ki.2010.194
  contributor:
    fullname: Yilmaz
– volume: 23
  start-page: 939
  issue: 6
  year: 2008
  ident: 2024020318340624200_jbmr1985-bib-0023
  article-title: Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro
  publication-title: J Bone Miner Res.
  doi: 10.1359/jbmr.080220
  contributor:
    fullname: Wang
– volume: 73
  start-page: 1
  year: 1986
  ident: 2024020318340624200_jbmr1985-bib-0010
  article-title: A case-control design for epidemiologic cohort studies and disease prevention trials
  publication-title: Biometricka.
  doi: 10.1093/biomet/73.1.1
  contributor:
    fullname: Prentice
– volume: 79
  start-page: 1370
  issue: 12
  year: 2011
  ident: 2024020318340624200_jbmr1985-bib-0022
  article-title: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease
  publication-title: Kidney Int.
  doi: 10.1038/ki.2011.47
  contributor:
    fullname: Isakova
– volume: 26
  start-page: 857
  year: 2011
  ident: 2024020318340624200_jbmr1985-bib-0003
  article-title: Serum fibroblast growth factor-23 (FFGF-23) and fracture risk in elderly men
  publication-title: J Bone Miner Res.
  doi: 10.1002/jbmr.263
  contributor:
    fullname: Mirza
– volume: 28
  start-page: 563
  issue: 4
  year: 2013
  ident: 2024020318340624200_jbmr1985-bib-0005
  article-title: FGF23 production by osteocytes
  publication-title: Pediatr Nephrol.
  doi: 10.1007/s00467-012-2309-3
  contributor:
    fullname: Bonewald
– volume: 27
  start-page: 1141
  issue: 9
  year: 2009
  ident: 2024020318340624200_jbmr1985-bib-0028
  article-title: FGF23 is a putative marker for bone healing and regeneration
  publication-title: J Orthop Res.
  doi: 10.1002/jor.20857
  contributor:
    fullname: Goebel
– volume: 67
  start-page: 1120
  year: 2005
  ident: 2024020318340624200_jbmr1985-bib-0031
  article-title: Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients
  publication-title: Kidney Int.
  doi: 10.1111/j.1523-1755.2005.00178.x
  contributor:
    fullname: Kazama
– volume: 9
  start-page: 336
  year: 2005
  ident: 2024020318340624200_jbmr1985-bib-0032
  article-title: Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients
  publication-title: Ther Apher Dial.
  doi: 10.1111/j.1744-9987.2005.00293.x
  contributor:
    fullname: Koiwa
– volume: 59
  start-page: 233
  year: 2011
  ident: 2024020318340624200_jbmr1985-bib-0021
  article-title: Mortality risk in older men associated with changes in weight, lean mass, and fat mass
  publication-title: J Am Geriatr Soc.
  doi: 10.1111/j.1532-5415.2010.03245.x
  contributor:
    fullname: Lee
– volume: 145
  start-page: 3087
  year: 2004
  ident: 2024020318340624200_jbmr1985-bib-0007
  article-title: Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha I collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis
  publication-title: Endocrinology.
  doi: 10.1210/en.2003-1768
  contributor:
    fullname: Larsson
– volume: 281
  start-page: 6120
  issue: 10
  year: 2006
  ident: 2024020318340624200_jbmr1985-bib-0027
  article-title: Regulation of fibroblast growth factor-23 signaling by klotho
  publication-title: J Biol Chem.
  doi: 10.1074/jbc.C500457200
  contributor:
    fullname: Kurosu
– volume: 69
  start-page: 341
  year: 2007
  ident: 2024020318340624200_jbmr1985-bib-0001
  article-title: Phosphatonins and the regulation of phosphate homeostasis
  publication-title: Annu Rev Physiolo.
  doi: 10.1146/annurev.physiol.69.040705.141729
  contributor:
    fullname: Berndt
– volume: 18
  start-page: 1227
  issue: 7
  year: 2003
  ident: 2024020318340624200_jbmr1985-bib-0018
  article-title: Serum FGF23 levels in normal and disordered phosphorus homeostasis
  publication-title: J Bone Miner Res.
  doi: 10.1359/jbmr.2003.18.7.1227
  contributor:
    fullname: Weber
– volume: 58
  start-page: 682
  year: 2011
  ident: 2024020318340624200_jbmr1985-bib-0015
  article-title: Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values
  publication-title: Am J Kidney Dis.
  doi: 10.1053/j.ajkd.2011.05.019
  contributor:
    fullname: Inker
– volume: 26
  start-page: 557
  issue: 5
  year: 2005
  ident: 2024020318340624200_jbmr1985-bib-0009
  article-title: Overview of recruitment for the osteoporotic fractures in men study (MrOS)
  publication-title: Contemp Clin Trials.
  doi: 10.1016/j.cct.2005.05.005
  contributor:
    fullname: Blank
– volume: 303
  start-page: F431
  issue: 3
  year: 2012
  ident: 2024020318340624200_jbmr1985-bib-0029
  article-title: Metabolic acisois increase fibroblast growth factor 23 in neomatula mouse bone
  publication-title: Am J Physiol Renal Physiol.
  doi: 10.1152/ajprenal.00199.2012
  contributor:
    fullname: Krieger
– volume: 28
  start-page: 899
  issue: 4
  year: 2012
  ident: 2024020318340624200_jbmr1985-bib-0030
  article-title: Pharmacological inhibition of FGFR signaling ameliorates FGF23-mediated hypophosphatemic rickets
  publication-title: J Bone Miner Res.
  doi: 10.1002/jbmr.1810
  contributor:
    fullname: Wšhrle
– volume: 94
  start-page: 2773
  year: 2009
  ident: 2024020318340624200_jbmr1985-bib-0020
  article-title: Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men
  publication-title: J Clin Endocrinol Metab.
  doi: 10.1210/jc.2008-2786
  contributor:
    fullname: Ensrud
– volume: 18
  start-page: 1227
  issue: 7
  year: 2003
  ident: 2024020318340624200_jbmr1985-bib-0025
  article-title: Serum FGF23 levels in normal and disordered phosphorus homeostasis
  publication-title: J Bone Miner Res.
  doi: 10.1359/jbmr.2003.18.7.1227
  contributor:
    fullname: Weber
– volume: 58
  start-page: 381
  issue: 6
  year: 2009
  ident: 2024020318340624200_jbmr1985-bib-0024
  article-title: FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling
  publication-title: J Electron Microsc (Tokyo).
  doi: 10.1093/jmicro/dfp032
  contributor:
    fullname: Ubaidus
– start-page: 169
  volume-title: Osteoporosis
  year: 2007
  ident: 2024020318340624200_jbmr1985-bib-0006
  contributor:
    fullname: Bonewald
– volume: 26
  start-page: 569
  issue: 5
  year: 2005
  ident: 2024020318340624200_jbmr1985-bib-0008
  article-title: Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study—a large observational study of the determinants of fracture in older men
  publication-title: Contemp Clin Trials.
  doi: 10.1016/j.cct.2005.05.006
  contributor:
    fullname: Orwoll
– volume: 91
  start-page: 3055
  issue: 8
  year: 2006
  ident: 2024020318340624200_jbmr1985-bib-0013
  article-title: C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status
  publication-title: J Clin Endocrinol Metab.
  doi: 10.1210/jc.2006-0710
  contributor:
    fullname: Singh
– volume: 59
  start-page: 1
  issue: 1
  year: 1999
  ident: 2024020318340624200_jbmr1985-bib-0014
  article-title: Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System
  publication-title: Scand J Clin Lab Invest.
  doi: 10.1080/00365519950185940
  contributor:
    fullname: Erlandsen
– volume: 22
  start-page: 211
  issue: 2
  year: 2007
  ident: 2024020318340624200_jbmr1985-bib-0011
  article-title: Predictors of nonspine fracture in elderly men: the MrOS study
  publication-title: J Bone Miner Res.
  doi: 10.1359/jbmr.061017
  contributor:
    fullname: Lewis
– volume: 38
  start-page: 1310
  year: 2006
  ident: 2024020318340624200_jbmr1985-bib-0004
  article-title: Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism
  publication-title: Nat Genet.
  doi: 10.1038/ng1905
  contributor:
    fullname: Feng
SSID ssj0006566
Score 2.386557
Snippet ABSTRACT Normal mineral metabolism is critical for skeletal integrity, and recently serum fibroblast growth factor 23 (FGF23) levels were found to be directly...
Normal mineral metabolism is critical for skeletal integrity, and recently serum fibroblast growth factor 23 (FGF23) levels were found to be directly related...
Normal mineral metabolism is critical for skeletal integrity and recently serum fibroblast Growth factor 23 (FGF23) levels were found to be directly related to...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 2325
SubjectTerms Aged
Demography
FGF23
Fibroblast Growth Factors - blood
Glomerular Filtration Rate
Humans
Incidence
Kidney - physiopathology
Male
MEN
OSTEOPOROSIS
Osteoporotic Fractures - blood
Osteoporotic Fractures - epidemiology
Osteoporotic Fractures - physiopathology
Risk Factors
Title Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: The Osteoporotic Fractures in Men (MrOS) study
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjbmr.1985
https://www.ncbi.nlm.nih.gov/pubmed/23677793
https://www.proquest.com/docview/1442743834
https://search.proquest.com/docview/1443999327
https://search.proquest.com/docview/1464507526
https://pubmed.ncbi.nlm.nih.gov/PMC3805817
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF5BT1ygDx4upRoQQunB1N6HnYVTgZqqUlpEQOJmrbO7FKTYVRIf-A_8aGbWiUlUgZC4WJY9ljfeb2a_2ex8y9hzoxM1tNrHlc59LCcZj43gkzhPvE2FTREjVJx8Ns4vvgzfnZJMzutVLUynD9FPuJFnhHhNDm6q-fFv0dDv1XT2ElNmKjDHLCGUb4gPfRQmntIxSFpoIdKVqlDCj_snN8eiGwTz5jrJdf4aBqDi3n81fZvdXfJOOOmAssNuuXqX7Z3UmHNPf8ALCCtBwxT7Hvu51mfQeECUtlPw-MqmQrK9gK-Yuy-uoNurB7iAQfG-4OIITG2BJu-p-hc8FWC1mM7jJWhoN3CYuvoVIDLhEsHVIPVvsDlQrBuOXA2D0exyfARB-vY--1ycfnp7Fi93bYgnCgNAXCntkUZYJYXhqa3wwNNMcy-9zzIujdfC5jIxSmvkTrn36QTjDFINJ51SRjxgW3VTu0cMLMJcGC1wHOfSphVSOafwAWG9S4xTEXu26r_yuhPnKDsZZl7SNy7pG0fsYNWz5dI_55jwSEzHMTuXEXva30bPor9LTO2aNtgge0N-m__NJpPIqBXPIvawA0vfEtLGyzH8RSzfgFFvQMrem3fqb1dB4VsM0YNSfO8gwOjPP648fzP6SCf7_276mN3htKdHKKg8YFuLWeuesNtz2x4GF8Lj-PziFwGzIYY
link.rule.ids 230,315,782,786,887,1408,27933,27934,46064,46488
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoOcCFV3kECgwIoe0hNPEj2SAuBRoW6LaIFolb5KxtCtI6aLs58B_40cw4u2FXFQiJS7RKJoo3_mb8jeP5zNgTXSRqaAoX10XuYjnJeKwFn8R54kwqTIoYoeLk0XF--Hn4ep9kcl4sa2E6fYh-wo08I8RrcnCakN79rRr6rZ7OnmHOrDbYRZkhEKmAQ3zo4zAxlY5D0lILkS51hRK-29-6Phqdo5jnV0quMtgwBJVX_6_x19iVBfWEvQ4r19kF62-wrT2Paff0BzyFsBg0zLJvsZ8r3QaNAwRqOwWHz2xq5Ntz-ILp-_wUuu16gAsYlG9KLnZAewM0f08FwOCoBqvFjB5PQUMbgsPU-ueA4IQjxFeD7L_B5kC5aji2Hgbj2dHxDgT125vsU7l_8moULzZuiCcKY0Bcq8IhkzBKCs1TU-OBp1nBnXQuy7jUrhAml4lWRYH0KXcunWCoQbZhpVVKi1ts0zfe3mFgEOlCFwKHci5NWiObswpvEMbZRFsVscfLDqy-d_ocVafEzCt6xxW944htL7u2WrjoGeY8EjNyTNBlxB71l9G56IuJ9rZpgw0SOKS4-d9sMomkWvEsYrc7tPQtIXm8HCNgxPI1HPUGJO69fsV_PQ0i32KITpTicwcBR3_-c9W7l-OP9OPuv5s-ZJdGJ-OD6uDt4ft77DKnLT5CfeU225zPWnufbZyZ9kHwp19TLSSi
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RIiEuvMojUGBACG0PoYkfyRpOhTaUx7YVLRK3yFnbFKRNqu3mwH_gRzN2dsOuKhASl2iVTBRv_M34G8fzGeCZVokcGuXiSuUuFuOMxZqzcZwnzqTcpIQRX5y8f5wffBnu7nmZnFeLWphOH6KfcPOeEeK1d_Az47Z_i4Z-rybTF5QyyzW4LIiGe-F8zo_6MOyJSkch_UoLni5khRK23d-6OhhdYJgXF0ouE9gwAhXX_6vtN-DanHjiToeUm3DJ1rdgY6empHvyA59jWAoa5tg34OdSp2HjkGDaTtDRI5uK2PYMv1LyPjvFbrMeZBwHxduC8S3UtUE_e-_Lf9H5CqyW8nk6hY3fDhwntn6JBE08JHQ1xP0bag4Wy4YjW-NgND083sKgfXsbPhd7J2_24_m2DfFYUgSIK6kc8QgjBdcsNRUdWJop5oRzWcaEdoqbXCRaKkXkKXcuHVOgIa5hhZVS8zuwXje1vQdoCOdcK04DORMmrYjLWUk3cONsoq2M4Omi_8qzTp2j7HSYWenfcenfcQSbi54t5w56ThmPoHyc0nMRwZP-MrmW_16ia9u0wYboGxHc_G82mSBKLVkWwd0OLH1LvDheTvEvgnwFRr2Bl_ZevVJ_Ow0S33xILpTScwcBRn_-c-X716NP_sf9fzd9DFeOdovy47uDDw_gKvP7e4Tiyk1Yn01b-xDWzk37KHjTL7B7I0g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+of+serum+fibroblast+growth+factor+23+%28FGF23%29+and+incident+fractures+in+older+men%3A+The+Osteoporotic+Fractures+in+Men+%28MrOS%29+study&rft.jtitle=Journal+of+bone+and+mineral+research&rft.au=Lane%2C+Nancy+E&rft.au=Parimi%2C+Neeta&rft.au=Corr%2C+Maripat&rft.au=Yao%2C+Wei&rft.date=2013-11-01&rft.issn=0884-0431&rft.eissn=1523-4681&rft.volume=28&rft.issue=11&rft.spage=2325&rft.epage=2332&rft_id=info:doi/10.1002%2Fjbmr.1985&rft.externalDBID=10.1002%252Fjbmr.1985&rft.externalDocID=JBMR1985
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0884-0431&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0884-0431&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0884-0431&client=summon